A Pilot Randomised Controlled Trial Involving Financial Incentives to Facilitate Hepatitis C Treatment Uptake Among People Who Inject Drugs: ETHOS Engage Study.

Autor: Marshall AD; The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.; Centre for Social Research in Health, UNSW Sydney, Sydney, NSW 2052, Australia., Conway A; The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia., Cunningham EB; The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia., Valerio H; The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia., Silk D; The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia., Alavi M; The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia., Tillakeratne S; The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia., Wade A; Drug and Alcohol Clinical Services, Mid North Coast Local Health District, Kempsey, NSW 2440, Australia., Lam T; Drug and Alcohol Clinical Services, Western Sydney Local Health District, Sydney, NSW 2770, Australia., Zohrab K; Lismore Liver Clinic, Mid North Coast Local Health District, Lismore, NSW 2480, Australia., Dunlop A; Drug and Alcohol Clinical Services, Hunter New England Local Health District, Newcastle, NSW 2302, Australia., Connelly C; North Metro Community Alcohol & Drug Service, Joondalup, WA 6027, Australia., Cock V; Drug and Alcohol Services South Australia (DASSA), Adelaide, SA 5069, Australia., Burns C; Drug and Alcohol Clinical Services, South Western Sydney Local Health District, Sydney, NSW 2170, Australia., Henderson C; NSW Users and AIDS Association, Sydney, NSW 2010, Australia., Christmass M; National Drug Research Institute, Curtin University, Perth, WA 6102, Australia.; Next Step Community Alcohol and Drug Services, East Perth, WA 6004, Australia., Dore GJ; The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia., Grebely J; The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.
Jazyk: angličtina
Zdroj: Viruses [Viruses] 2024 Nov 12; Vol. 16 (11). Date of Electronic Publication: 2024 Nov 12.
DOI: 10.3390/v16111763
Abstrakt: The primary aim of this study was to establish the feasibility of implementing a larger RCT designed to evaluate the effect of financial incentives on HCV treatment initiation among persons receiving opioid agonist therapy and/or who have injected drugs in the prior six months. ETHOS Engage is an observational cohort of participants recruited from drug treatment and needle and syringe programs in Australia. Among 11 drug and alcohol clinics, participants who were HCV RNA-positive were randomized (1:1) to receive standard of care or a AUD $60 gift card at treatment initiation. Regarding feasibility, 100% (57/57) of eligible participants enrolled to take part. Twenty-eight participants were randomised to the financial incentive arm (AUD $60 gift card) plus standard of care and 29 participants to the standard of care arm. In this pilot RCT (n = 57), median age was 42 years (IQR 37-49), 63% were male (n = 36), 35% Indigenous (n = 20) and 36% (n = 21) reported injecting drugs daily in the past month. Twelve weeks post-study enrolment, 11 (39%) participants in the financial incentive arm and 17 (59%) participants in the standard of care arm initiated HCV treatment. Findings indicate high feasibility among people who inject drugs to be randomised to receive financial incentives to initiate HCV treatment.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje